羚锐品牌怎么样 申请店铺

我要投票 羚锐在中草药行业中的票数:767 更新时间:2025-11-22
羚锐是哪个国家的品牌?「羚锐」是 河南羚锐制药股份有限公司 旗下著名品牌。该品牌发源于河南,由创始人熊伟在1999-04-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力羚锐品牌出海!将品牌入驻外推网,定制羚锐品牌推广信息,可以显著提高羚锐产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

羚锐怎么样

河南羚锐制药股份有限公司始创于1992年6月,由河南省信阳羚羊山制药厂和香港锐星企业公司合资组建而成,2000年10月成功上市,成长为国内知名制药企业。目前,公司在北京、上海、武汉、郑州、信阳等地控股、参股十余家企业,拥有多个科研、生产基地,其中羚锐新县生态工业园为国内最大的橡胶膏剂药品生产基地,羚锐信阳科技园为国内先进的大型口服药生产基地,建立在北京的羚锐药物研究院和羚锐伟业科技有限公司为公司的科技研发基地。公司资产总额10亿元,年创利税逾亿元,已成为当地经济发展的支柱企业。

公司拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂等十大剂型百余种产品,其中包括通络祛痛膏(骨质增生一贴灵)、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊等独家拥有知识产权的产品及国家中药保护品种和国家医保药品。公司的所有产品剂型及其生产车间均通过国家GMP认证,质量标准实现了与国际接轨。

公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国医药优秀企业”、“国家知识产权试点单位”,1999年和2005年先后两次被中央文明委表彰为“全国精神文明建设工作先进单位”,2001年被国家科技部认定为“国家火炬计划重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”;2002年“羚锐”商标被国家工商行政管理总局认定为“中国驰名商标”,成为国内橡胶膏剂药业中首件驰名商标。藉此,羚锐制药被业界誉为“中国橡胶膏剂药业第一品牌”。

浴火淬炼,十数年磨剑,羚锐始崛起,并稳健前进。

以“诚信立业,造福人类”为本,弘“团结、进取、创新、奉献”之志,坚持创新,实施人才兴企战略,以高新技术与传统药理、现代理念与先进文化完美融合,构筑企业平台,共享发展资源,我们将进一步提升核心竞争力,着力打造医药的优秀企业,成就百年基业。

Henan Lingrui Pharmaceutical Co., Ltd. was founded in June 1992 by Henan Xinyang lingyangshan pharmaceutical factory and Hong Kong Ruixing enterprise company. It was successfully listed in October 2000 and grew into a well-known pharmaceutical enterprise in China. At present, the company holds and shares more than ten enterprises in Beijing, Shanghai, Wuhan, Zhengzhou, Xinyang and other places, and has many scientific research and production bases. Among them, Lingrui new County Ecological Industrial Park is the largest rubber paste drug production base in China, Lingrui Xinyang science and technology park is the advanced large oral drug production base in China, and Lingrui Drug Research Institute and Lingrui Weiye science and technology established in Beijing Ltd. is the R & D base of the company. The company has a total assets of 1 billion yuan and an annual income tax of more than 100 million yuan, which has become a pillar enterprise of local economic development. The company has more than 100 kinds of products in ten dosage forms including rubber plaster, tablet, capsule, granule and tincture, including Tongluo Qutong plaster (hyperosteogeny Yitieling), Peiyuan Tongnao capsule, Danlu Tongdu tablet, Weitongning tablet, Shenqi Jiangtang Capsule and other products with exclusive intellectual property rights, national traditional Chinese medicine protection varieties and national medical insurance drugs. All the dosage forms and production workshops of the company have passed the national GMP certification, and the quality standards have been in line with the international standards. The company has been awarded as "top 50 enterprises of Chinese medicine industry", "advanced collective of Chinese medicine system", "excellent enterprise of Chinese medicine" and "pilot unit of national intellectual property". In 1999 and 2005, the company was awarded as "advanced unit of national spiritual civilization construction" by the central civilization Committee. In 2001, the company was recognized as "key high and new technology of national Torch Plan" by the Ministry of science and technology In 2002, "Lingrui" trademark was recognized as "China's well-known trademark" by the State Administration for Industry and commerce, and became the first well-known trademark in the domestic rubber paste pharmaceutical industry. Therefore, Lingrui pharmaceutical is known as "the first brand of Chinese rubber paste pharmaceutical industry". Bath fire quenching, more than ten years of sword sharpening, antelope sharp began to rise, and steady progress. Based on the principle of "building a business in good faith and benefiting mankind", we will carry out the strategy of "uniting, enterprising, innovating and dedicating", persist in innovation, carry out the strategy of developing an enterprise with talents, perfectly integrate high and new technology with traditional pharmacology, modern concept and advanced culture, build an enterprise platform and share development resources. We will further enhance our core competitiveness and strive to build an excellent enterprise in medicine, Achieve a century long foundation.

本文链接: https://brand.waitui.com/e8963bc9e.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

报告:“成分党”成为美妆主流消费群体

毕马威近日发布的《"颜"值经济新篇章:2025年中国美妆市场行业报告》(以下简称《报告》)显示,据调查,58.8%的消费者将产品成分作为购买决策的首要考量因素,“成分党”成为主流消费群体。与此同时,300-500元中端价格带产品市场份额显著提升,而超低价与高端市场则双双承压,反映出消费者在追求"悦己"体验的同时,更加注重产品的实际功效与性价比。(新浪财经)

2小时前

美联储传声筒:鲍威尔不是降息的最大障碍 美联储内部共识机制濒临瓦解

“美联储传声筒”Nick Timiraos撰文称,特朗普本周表示,他预计在明年5月任命新的美联储主席后,利率将大幅下降。然而,美联储内部反对12月降息声浪越来越大,这意味着他的愿望可能难以实现。无论鲍威尔在12月选择按兵不动还是降息,他都面临近八年任期内最严重的内部阻力。这种分歧可能延续至明年,这意味着,即便更换主席,也并不等于就能确保会有更多降息。一些人担忧,若特朗普无法如愿以偿,可能会采取更激进手段削弱央行独立性,以换取降息。(金十数据APP)

2小时前

第八届进博会,上海合作交流采购团达成意向采购额7.12亿元

11月21日下午,第八届中国国际进口博览会上海市合作交流采购团总结展示交流活动在闵行区虹桥品汇成功举办。据介绍,本届进博会上海市合作交流采购团采购成交再创新高,共达成意向采购额7.12亿元人民币,比上届提升4.71%,累计意向采购额突破30亿元。采购团规模也进一步扩大,分团总数增至33家,共组织30批次、近760人次走进进博会参观交流,参与企业数量创历年新高。(界面新闻)

2小时前

《哪吒2》不参加奥斯卡竞逐

当地时间11月21日,奥斯卡奖的主办方美国电影艺术与科学学院公布了符合资格参与最佳纪录长片、最佳国际影片以及最佳动画长片三个奖项竞逐的影片大名单。在最佳动画长片领域,今年有35部影片有资格“冲奥”,意外的是,《哪吒之魔童闹海》并不在其中。另一方面,《罗小黑战记2》榜上有名。(澎湃新闻)

2小时前

IDEA研究院孵化企业视启未来获近亿元融资

36氪获悉,孵化自IDEA研究院的视觉大模型企业,视启未来(深圳)科技有限公司宣布完成近亿元天使轮融资。本轮由A股上市公司安凯微领投,昊辰资本、德虎资本、元禾璞华、银杏谷资本、力合中科、数字未来、九安智能等机构跟投。

2小时前

本页详细列出关于羚锐的品牌信息,含品牌所属公司介绍,羚锐所处行业的品牌地位及优势。
咨询